Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 5/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19212425 | 0.98 | IDO1 (0.34) | IDO1SLC6A4SLC6A3POLBCYP3A4 | |
| SCHEMBL19212398 | 0.92 | SLC6A4 (0.32) | SLC6A4SLC6A3POLBCYP3A4CYP2D6 | |
| SCHEMBL19212408 | 0.91 | PIK3CD (0.33) | SLC6A4SLC6A3POLBCYP3A4CYP2D6 | |
| SCHEMBL19243610 | 0.89 | SLC6A4 (0.31) | SLC6A4SLC6A3POLBCYP3A4CYP2D6 | |
| SCHEMBL19212426 | 0.89 | PIK3CD (0.33) | SLC6A4SLC6A3POLBCYP3A4CYP2D6 | |
| SCHEMBL19243418 | 0.85 | SLC6A4 (0.35) | SLC6A4SLC6A3PDE4APDE4BPDE4C | |
| SCHEMBL19212436 | 0.85 | SLC6A4 (0.35) | SLC6A4SLC6A3POLBCYP3A4CYP2D6 | |
| SCHEMBL19243481 | 0.83 | SLC6A4 (0.35) | SLC6A4SLC6A3POLBCYP3A4CYP2D6 | |
| SCHEMBL30783370 | 0.83 | SLC6A4 (0.35) | SLC6A4SLC6A3POLBCYP3A4CYP2D6 | |
| SCHEMBL19212397 | 0.83 | IDO1 (0.35) | IDO1POLBNPSR1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11969425-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | INVENTISBIO LLC (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2023-10-26 | — | — | US | disclosed |
| EP-3414224-B1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-02-24 | — | — | US | disclosed |
| US-10980807-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | INVENTISBIO LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10980807-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | INVENTISBIO LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200046697-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2020-02-13 | — | — | US | disclosed |
| US-20200046697-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2020-02-13 | — | — | US | disclosed |
| EP-3414224-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | Inventisbio Inc. (KY) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139414-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO INC. (KY) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139414-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO INC. (KY) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | IDO1 1/4885SLC6A4 554/4885SLC6A3 1034/4885 |
| US-11969425-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | IDO1, IDO2, INMT | IDO1 1/4885SLC6A4 554/4885SLC6A3 1034/4885 |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | IDO1 1/4885SLC6A4 554/4885SLC6A3 1034/4885 |
| US-20200046697-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | IDO1 1/4885SLC6A4 554/4885SLC6A3 1034/4885 |
| US-10980807-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | IDO1, IDO2, INMT | IDO1 1/4885SLC6A4 554/4885SLC6A3 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.